OKYO Pharma CDO buys 3,500 shares of stock

OKYO Pharma Ltd reported an amended insider transaction for Chief Development Officer Gary S Jacob.

Accepted by SEC EDGAR 08/07/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd reported an amended insider transaction for Chief Development Officer Gary S Jacob. The amendment only corrects the code for an open market purchase on July 21, 2026, when he bought 3,500 common shares at $1.40, increasing his direct holdings to 112,420 shares.

Insider Trade Summary

Net Buyer: 3,500 shares

Net Buy 1 txn

Insider JACOB GARY S

Role CHIEF DEVELOPMENT OFFICER

Bought 3,500 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	3,500	$1.40	$5K

Holdings After Transaction: COMMON STOCK — 112,420 shares (Direct)

Key Figures

Shares purchased: 3,500 shares Purchase price: $1.40 per share Post-transaction holdings: 112,420 shares

3 metrics

Shares purchased 3,500 shares Open market common stock purchase on July 21, 2026

Purchase price $1.40 per share Price for common stock bought on July 21, 2026

Post-transaction holdings 112,420 shares Direct common stock owned by Gary S Jacob after the purchase

Key Terms

open market purchase, Form 4/A, non-derivative

3 terms

open market purchase financial

"correct the transaction code associated with this open market purchase"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

Form 4/A regulatory

"This Form 4/A amends the Form 4 filed on July 23, 2026"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

non-derivative financial

"transaction_type: non-derivative for the common stock purchase"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO (OKYO Pharma Ltd) report in this Form 4/A?

The amended report shows an open market purchase of 3,500 OKYO Pharma common shares at $1.40 per share on July 21, 2026, by Chief Development Officer Gary S Jacob, classified as a non-derivative transaction.

Why was the OKYO (OKYO Pharma Ltd) insider report amended?

The amendment corrects only the transaction code for the previously reported open market purchase. It states that no other reported transactions are affected, so the underlying share amount, price, and holdings remain unchanged.

How many OKYO (OKYO Pharma Ltd) shares does the insider own after this trade?

After buying 3,500 shares, Gary S Jacob directly owns 112,420 OKYO Pharma common shares. This total reflects his reported direct ownership immediately following the July 21, 2026 open market purchase.

Was the OKYO (OKYO Pharma Ltd) insider trade made under a Rule 10b5-1 plan?

No. The report’s Rule 10b5-1 checkbox is marked false, indicating the 3,500-share open market purchase at $1.40 per share was not executed pursuant to a Rule 10b5-1 trading plan.

What type of security and transaction is reported for OKYO (OKYO Pharma Ltd)?

The transaction involves common stock of OKYO Pharma in a non-derivative open market purchase. On July 21, 2026, the insider acquired 3,500 shares at $1.40 per share, increasing his reported direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JACOB GARY S

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF DEVELOPMENT OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		P		3,500	A	$1.4	112,420	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A amends the Form 4 filed on July 23, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.

	/s/ Gary Jacob	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)